U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	**SERIAL NO.:** 08/815,362
APPLICANT: Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE: March 21, 2001	**GROUP:** Not Known

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
TDH	AA	5,077,292	12/31/1991	Gluchowski			
	AB	5,034,406	7/23/1991	Gluchowski			
	AC	5,021,416	6/4/1991	Gluchowski			
	AD	5,130,441	7/14/1992	Gluchowski			
	AE	5,066,664	11/19/1991	Gluchowski			
	AF	5,151,440	9/29/1992	Gluchowski			
	AG	5,112,822	5/12/1992	Gluchowski			
	AH	5.091,528	2/25/1992	Gluchowski			
	AI	5,231,096	7/27/1993	Gluchowski			
	AJ	5,198,442	3/30/1993	Gluchowski			
	AK	5,580,892	12/3/1996	Garst et al			
	AL	5,552,403	9/3/1996	Burke et al			
	AM	5,663,189	9/2/1997	Maurer et al			
	AN	5,215,991	6/1/1993	Burke et al			
	AO	5,180,721	1/19/1993	Burke et al			
	AP	5,561,132	10/1/1996	Burke et al			
	AQ	5,621,113	4/15/1997	Boyd et al			
	AR	RE 32,400	4/1987	Karjalainen et al	514	397	
	AS	4,443,466	4/1984	Karjalainen et al	424	274	
	AT	4,496,572	1/1985	Cross et al	514	337	
	AU	4,540,705	9/1985	Bailey	514	401	
	AV	5,151,526	9/1992	Hsu et al	548	315.1 X	
TDH	AW	5,750,720	5/1998	Boyd et al II	548	315.1	

EXAMINER Floyd D. Higel DATE CONSIDERED 09-18-2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	**SERIAL NO.:** 09/815,362
APPLICANT: Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE: March 21, 2001	**GROUP:** Not Known

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
1994	AX	0 194 984	9/17/1986	EPO			
	AY	0 304 910	3/1/1989	EPO			
	BB	WO 97/35858	10/2/1997	WIPO ~~PCT~~			
	BC	WO 97/31636	9/4/1997	WIPO ~~PCT~~			
	BD	WO 95/19968	7/27/1995	WIPO ~~PCT~~			
	BE	WO 97/03079	1/30/1997	WIPO ~~PCT~~			
	BF	WO 97/15302	5/1/1997	WIPO ~~PCT~~			
	BG	WO 95/16449	6/22/1995	WIPO ~~PCT~~			
	BH	WO 97/12874	4/10/1997	WIPO ~~PCT~~ ORION TOKYO			
	BI	WO 94/07866	4/14/1994	WIPO ~~PCT~~ ~~ORG~~			
	BJ	WO 96/01813	1/15/1996	WIPO ~~PCT~~			
	BK	1/242571	9/1989	JAPAN KIHARA ET AL			
1998	BL	4/267130	1992	JAPAN			

EXAMINER Floyd D. Hyde DATE CONSIDERED 09-18-2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	**SERIAL NO.:** 09/815,362
APPLICANT: Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE: March 21, 2001	**GROUP:** Not Known

OTHER PRIOR ART

(Including Author, Title, Date, Pertinent Pages, etc.)

TDH	BM		Bylund et al, 1994, Pharmacol Rev. 46, pp. 121-136, "International Union of Pharmacology Nomenclature of Adrenoceptors"
	BN		Shimizu et al, 1969, J. Neurochem. 16, pages 1609-1619, "A Radiosotopic Method For Measuring The Formation of Adenosine 3′, 5′-Cyclic Monophosphate in Incubated Slices Of Brain"
	BO		Messier et al, 1995, Pharmacol. Toxicol. 76, pages 308-311, "High Throughput Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neurotrophin Receptors in Living Mammalian Cells"
	BP		Neve et al, 1992, J. Biol. Chem. 267, pages 25748-25753, "Dopamine D2 Receptor Stimulation of Na+/H+ Exchange Assessed by Quantification of Extracellular Acidification"
	BQ		Williams et al, 1990, J. Auton. Pharmacol, 10, 247, pages 109-118, "α_2-adrenoceptor antisecretory responses in the rat jejunum"
	BR		Fondacaro et al, 1988, Vol. 247, No. 2, pages 481-486, "The Journal of Pharmacology and Experimental Therapeutics"
	BS		White et al, 1975, Communications/Synthesis, pages 602-3, "A Convenient Procedure for the Preparation of 2-endo-Hydroxy-cis-bicyclo [3.3.0]octane"
	BT		Conklin et al, Nature, 1993, Vol. 363, pages 274-6, "Substitution of three amino acids switches receptor specifity of $G_q\alpha$ to that of $G_1\alpha$"
	BU		Schaaf et al, J. Med. Chem. 1983, Vol. 26, pages 328-334, "Structure-Activity Studies of Configurationally Rigid Arylprostaglandins"
	BV		Kihara et al, "Preparation of imidazole derivatives as drugs", 6001 Chemical Abstracts, Columbus, Ohio, U.S. Vol. 112 (4/9/1996), No. 16, XP-002098179
TDH	BW		Zhang et al, "Medetomidine Analogs as α_2-Adrenergic Ligands. 3. Synthesis and Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with α_2-Adrenoceptors Involving a 'Methyl Pocket' ", J. Med. Chemc. 1997, 40. pgs. 3014-3024

EXAMINER Lloyd D. Higel DATE CONSIDERED 09-18-2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.